Actually what it means is that OWC did not persue
Post# of 15624
(Total Views: 595)
Posted On: 05/10/2017 11:38:48 AM
Actually what it means is that OWC did not persue the clinicaltrial.gov route. If so, then the exchange you had would have stated that. Instead, the response is that it hasn't been updated.
Who's responsibility is it to update something that critical to the future of the company?
No one can let things like this go if it's for the betterment of the company endeavor, regardless of what their endeavor is.
Not bashing, but they seem to be laxidasical about their paperwork and keeping it up to date. I have seen better positioned biopharmas go/going belly up because they did not keep up with required filings with the FDA/clinicaltrials.gov.
In addition, OWC announced that trial would begin "soon" through the filing and acceptance by clinicaltrials.gov-->NIH.
It is still my belief that the results from Israel will be submitted to Clinicaltrials.gov/NIH per agreements with Helsinki IRB protocol which the FDA accepts.
Only time will tell, but in the meantime, they need to understand that releasing pertinent news(AKA 8Ks) would solidify the base for OWC.
IMO, it seems like OWC has reached a point that they don't care about OWCP which they should. By releasing info and making the stock more valuable, they could in turn secure better financing deals. And really, that's what the market is about.
No conference touting the greatness of their product will build investor confidence. Solid results will and this is IMO where they are failing with the US clinical trial.
They trade on the US OTC market. They got financing through that. Are they just throwing that out when the company could drive the PPS much higher, paving the way to a better exchange and better financing to do what they want?
OKAY, rambling, but get my point?
Who's responsibility is it to update something that critical to the future of the company?
No one can let things like this go if it's for the betterment of the company endeavor, regardless of what their endeavor is.
Not bashing, but they seem to be laxidasical about their paperwork and keeping it up to date. I have seen better positioned biopharmas go/going belly up because they did not keep up with required filings with the FDA/clinicaltrials.gov.
In addition, OWC announced that trial would begin "soon" through the filing and acceptance by clinicaltrials.gov-->NIH.
It is still my belief that the results from Israel will be submitted to Clinicaltrials.gov/NIH per agreements with Helsinki IRB protocol which the FDA accepts.
Only time will tell, but in the meantime, they need to understand that releasing pertinent news(AKA 8Ks) would solidify the base for OWC.
IMO, it seems like OWC has reached a point that they don't care about OWCP which they should. By releasing info and making the stock more valuable, they could in turn secure better financing deals. And really, that's what the market is about.
No conference touting the greatness of their product will build investor confidence. Solid results will and this is IMO where they are failing with the US clinical trial.
They trade on the US OTC market. They got financing through that. Are they just throwing that out when the company could drive the PPS much higher, paving the way to a better exchange and better financing to do what they want?
OKAY, rambling, but get my point?
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼